Chairman, SVBF USA/Rising Tide
Ossama has co-managed over $1 billion of international technology funds in diverse leadership roles including EVP of Berkeley International in San Francisco, Chairman of Technocom Ventures in Paris, President of Newbridge Networks Holding in Canada, Senior Managing Director of Newbury Ventures, and Chairman of the Rising Tide Fund in Silicon Valley. In the eighties, Ossama had the opportunity to co-lead the mezzanine financing of 80+ Silicon Valley based IT companies that became spectacular successes, including: Adaptec, Cirrus Logic, Atmel, PMC-Sierra, LSI Logic, Linear Technologies, and Oracle. Their combined market value today exceeds $200 billion. In the last 25 years, Ossama was chairman or co-founder of seven cutting-edge startups in the U.S., UK, France and Switzerland including ACC in Santa Barbara (routers, acquired by Ericsson), Algety in Lannion (soliton transmission, acquired by Corvis), HighDeal in Caen (rating engines, acquired by SAP), HighWave in Bretagne (fiber optic amplifiers, Listed on Euronext), NetCentrex in Paris (VoIP, acquired by Comverse), nCipher in Cambridge (encryption, listed on LSE), and Zong in Menlo Park (acquired by eBay). Currently, Ossama serves as a member of the Board of Directors of Bank of the West in San Francisco. On the social entrepreneurship side, he is a charter member of the C100, a Silicon-Valley based association dedicated to mentoring and angel financing Canadian entrepreneurs. Ossama also served on the Board of Directors of the nonprofit Relief International, a nonprofit, focusing his efforts on social entrepreneurship and development of women in the Middle East. He was chairman of the board of TechWadi and the Egyptian American Society in Silicon Valley and vice-chairman of the Board of PSD, an NGO focused on providing one laptop per child for up to 130,000 Palestinian children in need of education. On the academic side, Ossama served on the Board of Advisors of Harvard University Center for Middle Eastern Studies and of UCSF Department of Ophthalmology, School of Medicine in San Francisco. He was appointed as the Willard Brown Distinguished Professor at the American University in Cairo School of Business, where he remains a member of the Board of Advisors. Ossama lectured on Management Science and Engineering at Stanford University and the University of San Diego, and on international business at UC Berkeley and Santa Clara University. He was also a guest speaker on entrepreneurship in diverse venues including the White House, the State Department, MIT, Harvard University, and the Commonwealth Club.
Chairman, SVBF Korea/NPI
Dr. Moon Kook-Hyun joined The Asia Foundation Board of Trustees in 2017. He is the president & CEO of Hansoll Textile Ltd, and the Chairman & CEO of the New Paradigm Institute. He is the former president and chief executive officer of Yuhan-Kimberly, Limited, a 70:30 joint venture company between Kimberly-Clark Corporation and Yuhan Corporation in Korea. Mr. Moon has been an environmental leader for 30+ years. He initiated “Keep Korea Green,” the first company-sponsored environmental campaign in Korea in 1984, which created mountain paths, “Forest for Schools,” “Forest for Life,” “Forest for Peace,” “Northeast Asia Forest Forum,” and numerous educational activities for students, newly-weds, and opinion leaders in the country. His efforts on environmental protection and education have been recognized by the United Nations Environmental Program with its prestigious award, named “Global 500 Roll of Honor,” in 1997. He also received the Asian Environmental Award from Korea/Japan Daily Consortium in 1998. Mr. Moon also served as president of the Creative Korea Party from 2007 to 2009. He received a bachelor’s degree in English and Business Administration from HanKook University of Foreign Studies and a master’s degree in Business Administration from Seoul National University
Chairman, International Electric Vehicle Expo
Dae-hwan Kim, Chairman of International Electric Vehicle Expo, is firmly committed to promoting electric vehicles and building carbon-free islands. His latest achievement is launching Global EV Association Network during the 3rd International Electric Vehicle Expo (IEVE 2016). Global EV Association Network is a non-profit body consisting of associations, institutions, and business entities from twelve countries in the fields of EVs, smart grid, renewable energy, and environment. Its objectives are to share information and execute collaborative actions in pursuit of EV deployment and to share best practices in the areas of government policies, business models, and public relations.
Principal, Rising Tide
Brent brings over 25 years of professional experience in industry and investing. Most recently, Brent led the Internet of Things (IoT) global marketing efforts for Hewlett Packard Enterprise Communications Media Solutions Business division. Prior to HPE, Brent spent six years in private equity financing at Newbury Ventures where his focus was on early stage global communication and IT companies. He assisted on investments and follow-up financing in several companies including Zong (acquired by e-Bay, Inc.), Sandvine Corp. (TSX:SVC), Abridean (acquired by nCipher, Inc.), LEA (acquired by HP Company, Inc.), Netcentrex (acquired by Comverse, Inc.), and Highwave Optical Technologies SA. He is also an Independent Director at Socket Mobile (NASDAQ: SCKT) and Quanergy and is an Associate with Creative Destruction Lab (CDL) West, a Canadian seed-stage program to bring the best ideas in the technology field to market. Brent holds Master level degrees from the London School of Economics and Carleton University.
Distinguished Fellow, Yeosijae
Professor of Gachun University
Former Vice-Minister of MSIP (Ministry of Science ICT and Future Planning, Korea)
Mr. Jong Lok Yoon is a professor of Gachun University in Korea. He is teaching Management of Innovations and contributes special advisor to the president of the University. He was the President of National IT Industry Promotion Agency of Korea (NIPA) since 2015. NIPA is an IT industry promotion organization operated by the Government of South Korea. Prior to this position, he served as the Vice Minister of Korean government at the Ministry of Science ICT and Future Planning (MSIP). During this period, he played a leading role in Government’s key initiative – Creative Economy, which focuses on boosting the economy through nurturing the startups and small/medium sized business in Korea. His strong partnerships with startup communities in Israel’s innovation hub continue to help his drive and thought leadership in fostering the innovation culture in Korea even after his ministry role.
Before he joined the government, he was invited to become a professor of Yonsei University in Seoul, Korea, which is one top ranked universities in Korea, at the school of convergence technology. Prior to that, he was senior executive consultant to the President of Bell Labs in New Jersey, U.S., which is one of the most prestigious telecommunications laboratories. His role as an executive consultant focused on the new strategies for the converged industries using ICT technology as a convergence enabler such as new concept of healthcare, automobile, education for the coming decade. He consulted on these issues to the president of Bell Labs with the collaboration of CTO of Alcatel-Lucent group.
He was a board of director and senior executive vice president of KT and has been leading the Growing Business Group until 2009. Prior to that, he served as head of R&D Group, New Business Planning Group, Marketing Group, and e-Biz Group. He also served as the President of KT America Inc. During these years, Mr. Yoon led transformation of KT from a traditional telephone company to a total solution provider and was credited to with formulating “Telco 2.0”, which was Telco’s new role and business model in the IP world for increasing customer value.
Mr. Yoon is Chairman of Telecommunication Technology Association of Korea, Korea Internet Telephony Forum, and Korea Institute of Information & Telecommunication Facilities Engineering. He is a distinguished member of Future Trend Forum (FTF) sponsored by Spanish bank Bankinter.
He received B.S. in Air Telecommunication Engineering at Korea Aerospace University and M.S. in Electronics and Engineering at Yonsei University in Korea. He also received Diploma in Telecommunications Police Analysis from Michigan State University.
He gives lectures and speeches in global fora and global and governmental institutes, and published best seller books in Korea specializing in the new industry revolution, startups and ICT. He is often featured in many newspaper articles and TV programmes as thought leader.
KBE, CBE FRS, FRSC, FREng FInstP - Amadeus Capital Partners
In 2015 Hermann was awarded an KBE for services to Engineering and Industry.
Serial Entrepreneur and Co-founder of Amadeus Capital Partners, Dr Hermann Hauser KBE has wide experience in developing and financing companies in the information technology sector. He co-founded a number of high-tech companies including Acorn Computers which spun out ARM, E-trade UK, Virata and Cambridge Network. Subsequently Hermann became vice president of research at Olivetti. During his tenure at Olivetti, he established a global network of research laboratories. Since leaving Olivetti, Hermann has founded over 20 technology companies. In 1997, he co-founded Amadeus Capital Partners. At Amadeus he invested in CSR, Solexa, Icera, Xmos and Cambridge Broadband.
Hermann is a Fellow of the Royal Society, the Institute of Physics, the Royal Society of Chemistry and of the Royal Academy of Engineering, as well as an Honorary Fellow of King's College, Cambridge. In 2001 he was awarded an Honorary CBE for ‘innovative service to the UK enterprise sector’. In 2004 he was made a member of the Government’s Council for Science and Technology and in 2013 he was made a Distinguished Fellow of BCS, the Chartered Institute for IT.
Hermann has honorary doctorates from the Universities of Loughborough, Bath, Anglia Ruskin, Strathclyde, Glasgow and York.
Founder, Activ Surgical
Dr. Peter C. W. Kim, MD, CM, PhD, is a pediatric surgeon and scientist, and past vice president of the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System. As Vice President, he implemented the Institute’s vision of innovative, multidisciplinary research and development in pediatric surgery. Dr. Kim’s research focuses on the development of smarter surgical tools, including image guidance and robotics; smarter simulation technologies that prepare tomorrow’s pediatric surgeons through a hands-on approach rather than the traditional lecture-based medical training model; and the potential of technologies such as high-intensity focused ultrasound (HiFU) as non-invasive alternatives to conventional surgery. He has authored more than 100 papers and 50 abstracts on a range of topics, with special emphasis on developmental molecular biology as well as innovation and technology, including minimally invasive surgical techniques. He is a world-renowned surgeon and medical technologist, is a founder of Activ Surgical and the inventor of its technology, which he developed over seven years with more than $13 million in non-dilutive grant funding. Previously, he served as Associate Surgeon-in-Chief of the Joseph E. Robert, Jr., Center for Surgical Care at Children’s National. He was also the lead for the FDA funded National Capital Consortium for Pediatric Device Innovation (NCC-PDI). Dr. Kim joined Children’s National from the Hospital for Sick Children in Toronto, Ontario, a national and international leading institution in pediatric research and care. Dr. Kim received his medical training, including the distinction of Master of Surgery, at McGill University. He completed his surgical residency training at the University of Toronto as well as his fellowship in pediatric surgery at the University’s Hospital for Sick Children. Linked-in Profile – see link here
Evonetix is focused on synthetic gene synthesis to facilitate the fast-growing field of synthetic biology. More information can be found at https://www.evonetix.com/
Long Form: Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesize DNA at unprecedented accuracy and scale. The company’s platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used. This new paradigm in gene synthesis will facilitate and enable the rapidly growing field of synthetic biology. More information can be found at https://www.evonetix.com/
Dr. Tim Brears, CEO: Dr. Tim Brears was appointed Chief Executive Officer of Evonetix in May 2017. Tim previously served as Chief Executive of a number of bioscience companies, including Xention, a biopharmaceutical company specializing in the discovery and development of ion-channel-modulating drugs for the control of atrial fibrillation, and Gendaq, a company focused on the development of zinc finger proteins for gene regulation. Prior to that, he spent ten years in the US, initially as a long-term fellow of the European Molecular Biology Organization at Rockefeller University, New York, and subsequently as Director of Licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina. Tim is a graduate of Oxford University and holds a PhD in molecular biology from Cambridge University. He also has an MBA from Duke University’s Fuqua School of Business and is a Registered US Patent Agent. Tim currently serves as chair of the Engineering Biology Advisory Committee of the BIA and is a member of the UK’s Synthetic Biology Leadership Council. LI profile: https://www.linkedin.com/in/tim-brears-a9280a33/
CEO, Activ Surgical
Activ Surgical is developing robotic systems for autonomous intestinal anastomosis in a preclinical porcine model. More information can be found at https://www.activsurgical.com/
Long Form: Activ Surgical, the company that completed the world’s first autonomous robotic surgery of soft tissue, is building hardware-agnostic surgical software that allows surgical systems to collaborate with surgeons. Activ Surgical’ s patent-protected surgical software platform reduces unintended and preventable surgical complications by enhancing a surgeon’s intra-operative decision making. More information can be found at https://www.activsurgical.com/
Mr. Todd Usen, CEO: Todd Usen is an accomplished and seasoned leader with more than 25 years of medical device and healthcare experience, and a proven track record of leading, developing and executing on commercialization strategies and driving market development initiatives for profitable growth. He joined Activ Surgical in January 2019 after serving as the President of the Medical Systems Group at Olympus Corporation of the Americas, where he helped lead the group’s expansion from six medical divisions to 11. Prior to joining the Olympus Corporation, Todd held the position of President, Orthopedics, at Smith and Nephew, overseeing the Total Joint, Sports Medicine and Trauma divisions. He held several other vital positions for Smith and Nephew including Senior Vice President and General Manager, Joint Reconstruction; Senior Vice President, Sports Medicine; and Senior Vice President, Endoscopy. Prior to Smith and Nephew, Todd worked for Boston Scientific as the Vice President of Sales for the Neurovascular division, Director of Endoscopy Sales, and Global Manager of Field Development. He holds a B.S. in Marketing from the University of Massachusetts Isenberg School of Business and did his M.B.A. work at Pepperdine University. LI profile: https://www.linkedin.com/in/toddusen/
President, CEO and Board Member, Molecular Assemblies
Molecular Assemblies is developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. More information can be found at https://molecularassemblies.com/
Long Form: Molecular Assemblies is a private biotechnology company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high-quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies’ technology will unleash a new generation of DNA synthesis for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines and bio-based electronics. More information can be found at https://molecularassemblies.com/
Mr. Michael J. Kamdar, President, Chief Executive Officer and Board Member: Michael Kamdar joined Molecular Assemblies in 2016 as President, CEO and Board Member. An industry veteran with an expertise in business development and financing, Michael has accounted for deal transactions in excess of $1 billion and has raised more than $400 million from venture capital and the public capital markets. Prior to joining Molecular Assemblies, he was President and Board Member for Ciclofilin Pharmaceuticals, a company focused on development of novel Hepatitis B (HBV) compounds, which was sold to ContraVir Pharmaceuticals in June 2016. Previously, he was President and Board Member of Cellana, a leading developer of algae-based products. He was also the Founder, Chief Business Officer, and Board Member of Genoa Pharmaceuticals, a company developing a treatment for idiopathic pulmonary fibrosis. Michael also founded VentiRx Pharmaceuticals, a privately held company focused on Toll-like Receptor 8 agonists (TLR8), which was optioned to Celgene Corporation in 2012. At VentiRx, he served as a Board Member and Chief Business Officer. Before founding VentiRx, Michael held several positions at Anadys Pharmaceuticals, most recently serving as Senior Vice President, Corporate Development and Finance, and played an instrumental role in the company’s successful IPO. Prior to Anadys, Michael served in senior management at Agouron Pharmaceuticals, a Pfizer Company, most recently as Vice President, Business Development. During his eight years at Agouron, he held positions of increasing responsibility, culminating with his assumption of global responsibility for corporate partnering, in-licensing, technology acquisition, and strategic alliance efforts in the anti-infective, oncology, and ophthalmology therapeutic areas. Michael is a member of the Board of Directors of Genoa Pharmaceuticals, Medipacs (Chairman), Prime Genomics and Vault Pharma. He received a Bachelor of Science in biology from St. Joseph’s University and a Masters of Business Administration from Villanova University. LI profile: https://www.linkedin.com/in/michael-kamdar-085a7aa/
CEO and Co-Founder, Precision NanoSystems
Precision NanoSystems creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. The company is uniquely positioned to offer the flexibility needed to move products from the clinical development stages through to commercial scale in a nimble and agile manner, accelerating the research and drug development process. More information can be found at http://www.precisionnanosystems.com
Long Form: Precision NanoSystems (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. More information can be found at http://www.precisionnanosystems.com
Dr. James Taylor, CEO and Co-Founder: Dr. James Taylor is the CEO and Co-Founder of Precision NanoSystems, (PNI), a commercial stage biotechnology company at the convergence of nanotechnology, genomics, and precision medicine. PNI empowers researchers to advance nanomedicines for the treatment and diagnosis of disease. James earned a B.A.Sc. in engineering physics from UBC and a Ph.D. in genetics from the Institute for Systems Biology in Seattle, WA. James worked at the Seattle based Venture Capital firm, the Accelerator Corporation concurrent with his Ph.D. and has extensive experience in the science and commercialization of microfluidics, nanotechnology, and systems biology. James has led PNI since its inception and has grown the Company to be the leading technology provider for the development of nanomedicines. James is a Director of Life Science British Columbia and an active participant of the bio-entrepreneurial community. LI profile: https://www.linkedin.com/in/taylorrobertjames/
CEO, TAE Life Sciences
TAE Life Sciences is creating a paradigm shift in cancer therapy. TAE Life Sciences has developed a noninvasive cancer treatment through Boron Neutron Capture Therapy. More information can be found at https://taelifesciences.com/
Long Form: TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers. TLS has assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists, and other researchers to enable it to bring this technology to cancer patients who need it most. TLS’s drug and device are currently in development and have not been approved for sale. More information can be found at https://taelifesciences.com/
Dr. Bruce Bauer, CEO: Dr. Bruce Bauer is Chief Executive Officer of TAE Life Sciences, having organized its founding with technology licensed from TAE Technologies. Bruce is an active investor and entrepreneur; he has spun out technology into new companies, developed products for international markets, and built management teams with cross border operations. Following a career in the medical imaging industry, Bruce entered the private equity industry, ultimately founding Newbury Ventures and spending decades in international venture capital-focused on healthcare, imaging, sensors, enterprise software, and industrial businesses. Before founding Newbury, Bruce was a Principal at Berkeley International Capital, directing the firm's investments in healthcare and software. There, he built and managed a broad investment portfolio of healthcare and technology companies. He is a co-founder and Chairman of WingInflatables and co-founded and was Chairman of Berkeley HealthEDU. Bruce has led investments in NextBio, Sentillion, Okena, PS'Soft, PacificEdge Software, Landmark Graphics, Nellcor, Sepracor, Lumisys, Crystal Semiconductor, Resound, Ventritex, Dianon Systems, and Protocol Systems. Bruce holds B.S.E. and Ph.D. degrees in Biomedical Engineering from Duke University. LI profile: https://www.linkedin.com/in/bruce-bauer/
CEO and Co-Founder, Exo Imaging
Exo Imaging is giving health care providers the tools they need to diagnose at the time of exam at significantly lower cost. The company brings affordable ultrasound to the masses. More information can be found at https://www.exo.inc/ Long Form: Exo Imaging is a developer of new diagnostic hardware for the medical industry. Cost, portability, image quality and the inability to image dense body compositions have all limited the impact that diagnostic tools like ultrasounds can have on patient care around the world. Exo Imaging solves that problem by building on a patented piezoelectric micromachined ultrasound transducer. Its device improves image quality, while an accompanying software toolkit boosts the diagnostic capabilities of the device. The Exo Imaging hardware comes with a suite of software tools that have been designed to integrate with existing workflows. The company has plans to use its initial foray into medical imaging as a way to land and expand into a broader suite of tools for the hospital or urgent care environment. The company envisions a multi-functional device that can perform a number of different diagnoses. More information can be found at https://www.exo.inc/ Mr. Sandeep Akkaraju, CEO and Co-Founder: Sandeep Akkaraju is a proven entrepreneur with a hands-on managerial background in leading interdisciplinary technology and business teams, and a track record of bringing to market complex hardware and software products. Exo is his fourth startup organization. Prior to founding Exo, Sandeep was Founder and President of Jyve Inc. (acquired by a major semiconductor corporation at an exit valuation of more than $60M). Previously, he was CEO of IntelliSense, a leading provider of micro-mechanical integrated circuits (MEMS) and nanotechnology-based software and solutions. Under his guidance, IntelliSense expanded its physical presence into China and India and its sales presence into 30+ countries. Sandeep helped the company rapidly grow from a startup to its eventual acquisition at a valuation of $750 million. In 2003, he led the re-acquisition of IntelliSense from Corning. Sandeep holds a B.Tech from the Indian Institute of Technology, an M.S. from LSU and an M.B.A. from INSEAD, France. LI profile: https://www.linkedin.com/in/sandeepakkaraju/
CEO & President, Aspect Biosystem
Aspect Biosystem is focused on drug development, personalized medicine, and regenerative medicine by becoming the global leader in 3D human tissue technology. More information can be found at https://www.aspectbiosystems.com/
Long Form: Aspect Biosystem is a biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect’s microfluidic 3D bioprinting platform and collaborating within Aspect’s network, researchers worldwide are accelerating the development and commercialization of 3D bioprinted tissues. Aspect is also advancing its internal regenerative medicine programs focused on metabolic diseases and musculoskeletal injuries and disorders and partnering with key industry players to bring bioprinted therapeutics to the clinic. More information can be found at https://www.aspectbiosystems.com/
Mr. Tamer Mohamed, CEO & President: An entrepreneur, engineer, inventor, Tamer Mohamed currently serves as Chief Executive Officer and President of Aspect Biosystems. Tamer co-founded Aspect in 2013 and has played a leading role in our overall corporate, business, and technology development. Under his leadership, the company has secured significant funding, entered strategic collaborations with best-in-class pharmaceutical and biotechnology companies, and developed our commercial products. In his previous appointment as Chief Technology Officer of the company, Tamer drove the innovation and development of the company’s core technologies and intellectual property. As a leader in the field of 3D bioprinting, he has been invited to speak on this topic at venues ranging from TEDx to industry, scientific, and executive conferences. In 2017, he was awarded BC's Top 40 under 40 award for demonstrating excellence in business, judgement, leadership, and community contribution. Tamer serves on the Board of Directors for ACETECH, a non-profit training and mentoring organization for CEOs of technology and life sciences companies, and on the Board of Directors for The Stem Cell Network, an organization focused on building Canada’s stem cell and regenerative medicine research sector. Tamer holds a B.A.Sc. in Biomedical Engineering and M.A.Sc. in Electrical and Computer Engineering from the University of British Columbia. LI profile: https://www.linkedin.com/in/tamer-mohamed-7961705a/
Medical director, Daejeon Wellness Hospital
Chul Jun KIM MD. EMBA is a medical director of Wellness Hospital Group and founder of two startups( Enterogenomics Inc., Wellness Healthcare Inc.)
Enterogenomics inc. is specialized company for pharmanutrition with microbiome, functional nutrition for cancer and metabolic syndrome. Wellness Healthcare Inc. is developing smart rehabilitation medical equipment and investor of a number of venture companies. During 2018-2020, our international project is Wellness Artificial Kidney Center in Malaysia and consultation of rehabilitation hospital in China. Wellness Bio-healthcare Forum(Healthcare companies with hospitals) in Daedeok Valleys was started by Wellness Hospital in 2018.
Our hospital's investment portfolio(2016-2020) in healthcare companies is as follows.
1) Y biologics : Ab therapeutics (Ab library Ymax®-ABL & Bi-specific Ab platform technology)
2) ENS healthcare : R&D and production of in vitro diagnostic medical devices and biomarkers
3) Biocurepharm : recombinant based biopharmaceuticals(CAR-T cell therapy)
4) Biochestra : RNA-based therapeutics(Alzheimer’s dementia)
5) Bluepoint partners : deep tech startup accelerator
6) ROWE partners : start-up accelerator based on public technology
7) Kainos medicine : innovative medicines for brain diseases, cancers, and infectious disease
8) Remedi : radiation medical equipment platform(HIFoX Technology)
9) M20 : muscle exercise & treatment equipment using EMS(medium-frequency) for sarcopenia
10) Bioinfra : innovative multi-biomarker blood test for cancer detection
11) QBM : technology to extract 70 kinds of trace minerals from deep ocean water
12) IM healthcare : digital healthcare company of bio-diagnosis tech, IoT Health and Ionizer
13) Ultra V : melting thread for sealing, medical devices, and high-performance cosmetics
We hope to create a network that will grow together with products and services that will lead the world by investing and researching together through this forum between Silicon Valley and Korean bio-companies
CEO and Founder, E&S Healthcare Inc.
Long Form: E&S Healthcare, the company is aiming to find innovative medical solutions that gurantee the 3A values (Availability, Accessibility, and Affordability) of in vitro diagnostic technology. In particuar, the company have developed or been developing diagnostic kits that use blood to diagnose gynecological cancers such as breast cancer (DxMe® BC), ovarian cancer (DxMe® OC), and endometriosis(DxMe® Endo) to ensure that woman can lead healthy life. In adition, a fully automated equipment (Elisure®) that utilizes those diagnostics easily for consistent diagnostic test quality has been developed. The company has contract-marketing partners for DxMe® BC in Germany, USA, and Malaysia. E&S Healthcare is committed to developing valuable healthcare solutions to meet the needs from clinical fileds such as non-invasive, simple, user-friendly and economic in vitro diagnstic technology and products. More information can be found at http://www.ens-h.com/
Dr. Ken Kyoung Hoon Suh, CEO and Founder Dr. Ken Kyoung Hoon Suh is the CEO and founder of E&S Healthcare, a commercial stage in vitro diagnostic company developing new and invaluable diagnostics from searching of novel or re-orienting protein biomarekrs from body fludis. Ken is a professor of Department of Biotechnology and Science, Pai Chai University since 1995. He has successfully completed a long-term government supporting project that formed a research cluster with industry, academia, and hospitals to discover biomarkers. Ken have been involved in many central and local governments’ planning and evaluation committees of bio-industry for over a decade. Ken earned a BS and a MS in biochemistry from Yonsei University. He had studied for a Ph.D. at Department of Phhysiology and Bioiphysics, University of Illinois at Chicago and worked at Department of Physiology and Pharmacology, University of Chicago as a post-doc and a research associate. He is serving as one of vice presidents of Bio-Healthcare Association that facilitates fruitful cooperation among all kinds of stakeholders in bio-economy.
CEO, RevoSketch Inc.
Mr. Sung Woon Lee studied Electricity and Electronic Engineering in KAIST (Korea Advanced Institute of Science and Technology).
In 1994, he designed 2 payloads (CFP, SENSE) of 13 payloads composed KITSAT-3(3rd satellite of Korea).
He is also a serial entrepreneur, AKCRON(1994), Star V-ray(2000), 3DISC(2007) and RevoSketch(2017). The companies introduced various products such as space related product, semiconductor inspection system, bio analyze system, medical device in the global market. In the past, he worked with large companies including SAMSUNG Techwin, Macrogen, Bioneer, and space-related companies such as SaTrec, SaTrec-I and ETRI, and overseas companies such as Contex, Vidar, Planmeca, JPI America.
He has experiences in the global marketing and global operations (oversea offices in Washington D.C. and Denmark).
Vice President , Sugentech Inc.
Sugentech is the major In-Vitro Diagnostics (IVD) and KOSDAQ-listed company in Korea, while its subsidiary named Modori-C is mobile healthcare App development company. JuneEun Lee has been working as CSO and CMO for Sugentech and CEO for Modori-C. Sugentech is FDA registered, ISO13485 certified IVD company with robust and exhaustive Bio-IT convergence technologies. Sugentech covers from R&D to manufacture of its IVD products, based on its own platforms such as Home-testing, professional Point-of-Care Testing, and Fully Automated immunoblot Lab System Dr. JungEun Joanna Lee, after getting PhD in Cell biology from Seoul National University, started her professional career in Accenture, Strategy Group and has played executive roles in various industry such as Yahoo, Doosan, Samyang Corp., General Motors (US and Korea) and Samsung for Operational group, Strategy, New Business Development, Program management and Marketing. The experience of various industry and different functions is of great help to configure the strategy and to lead the execution of the Bio-IT converging IVD company with a good acumen and agility. Her detailed profile could be found at : https://www.linkedin.com/in/jungeun-lee-10891341/
Ph.D./MBA, KRIBB (Korea Research Institute of Bioscience and Biotechnology)
Principal Research Scientist
SME Support Center
Korea Research Institute of Bioscience and Biotechnology
Heungchae Jung is currently a BD Coordinator and Principal Research Scientist at SME Support Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), since 1991, in Korea. Based on the bacterial cell surface display he has developed and other innovative protein expression platforms, he found a startup with his colleagues and the company is currently growing in the market. He had also led the technology licensing office in KRIBB from 2008 to 2014 to bridge the gap between the research laboratory and the real world applications of microorganisms. He has been focusing on business development in the field of microbiome therapeutics and synthetic biology. He is interested in bacterial and yeast probiotics as a therapeutic microorganism and developing a new microbiome for human healthcare treatment.
APAC Research Head , BloombergNEF
Based in Seoul, Ali Izadi manages BloombergNEF's research teams across Asia Pacific (Beijing, Hong Kong, New Delhi, Singapore, Sydney and Tokyo), focusing on the transition of the region's economies to a cleaner more competitive future. The teams’ reports and tools help clients identify opportunities and risks associated with this transition. Prior to his current role, Ali managed BloombergNEF’s Intelligent Mobility team as well as Japan and Korea Research team. Prior to joining BloombergNEF in 2010, Ali had worked at Japan’s National Institute of Advanced Industrial Science and Technology, as well as fuel cell manufacturer, Ballard Power Systems.
Ali has an undergraduate degree in Engineering Physics and a Masters in Electrical Engineering from the University of British Columbia, and a Doctorate in Materials Science from Meijo University.
CEO& Co-Founder, OneD Material
OneD Material is enabling large-scale manufacturing of nano-silicon attached to commercial graphite powders, enabling better, cleaner, and less expensive EV batteries. More information can be found at https://www.onedmaterial.com/
Dr. Vincent Pluvinage, CEO& Co-Founder: Dr. Vincent Pluvinage is the co-founder, CEO and Board member of OneD Material, Inc. (herein “OneD”), a leading Silicon Valley technology company based in Palo Alto, California, USA. In 2013, he led the spin-out of OneD from Nanosys, Inc. (the leading provider of Quantum Dot technologies for displays) with OneD acquiring all of the IP assets and the R&D team focused since 2004 on silicon nanotechnologies for fuel cells and lithium-ion batteries under the direction of Dr. Yimin Zhu (who then became co-founder and Chief Technology Officer of OneD). Working closely with several large lithium-ion cell makers, OneD’s SiNANOde® technology platform has become a leading manufacturing platform to add nano-silicon to commercial graphite already produced at large scale and used in EV batteries. This highly scalable and cost-effective manufacturing platform is now paving the way to increasing energy density (and therefore EV range), while decreasing costs and carbon footprint of EV batteries, Solar & Wind Energy Storage and other emerging applications. As a result of more than a decade of work, fueled by more than $100M of R&D investments, OneD’s IP portfolio now spans 200 granted worldwide patents covering silicon-carbon anode materials and production processes. Prior to 2013, Dr. Pluvinage led several Silicon Valley successful ventures, before creating Invention Capital Partners to provide capital and expertise to commercialize breakthrough innovations. Originally trained in Applied Physics at the Universite Catholique de Louvain (Belgium), where he graduated summa cum laude, he came to the US as a fellow of the Belgian American Educational Foundation to complete a PhD in Bioengineering, and subsequently became a member of the technical staff at AT&T Bell Laboratories. In 1987, he spun-out a technology from Bell Labs and became co-founder of ReSound in Silicon Valley, which he took public on Nasdaq in 1993 (Nasdaq: RSND). After doubling revenues every year for six consecutive years, ReSound was acquired and is now a leading global medical device company. In 1997, he co-founded and became CEO of Preview Systems, a software company that he took thru an IPO in 1999 (Nasdaq: PRVW). Later, he became CEO of IP Value Management Inc. and worked with British Telecom and Xerox on managing more than 20,000 patented inventions, before leading the Private Equity team at Intellectual Ventures, to provide IP to enable large commercial transactions, such as the building of the Iridium’s NEXT satellite constellation. Dr. Pluvinage experience in diverse areas of technology, ranging from medical device and software to material sciences and mobility, is combined with a deep understanding the importance of Intellectual Property assets to the adoption of new technologies by large companies seeking to transform markets (he is an inventor on more than 100 worldwide patents).
Advisor, Motus Ventures
Mr. Steve Wollenberg, Advisor Motus Ventures: Steve is a Venture Partner at Motus Ventures in Redwood City, CA, focusing on the intersection of key industries including Artificial Intelligence, Robotics, Connected Transportation, Smart Infrastructure, Energy, and Internet of Things (IoT). He is also co-founder and Vice President of Business Development and Operations at Automatiks, a venture funded Silicon Valley company focused on hybrid renewable energy systems, especially in emerging markets such as Africa, India, the South Pacific, and the Caribbean. Steve is a serial entrepreneur and has founded 3 additional Silicon Valley startups focused on transportation connected services, especially for electric vehicles and fleet mobility. LI profile: https://www.linkedin.com/in/swollenberg/
Advisor, NEWS 1 Korea
Mr. Kim Soo Jong is currently serving as a director at the International Electric Vehicle Expo Corporation, the co-chairman of the Jeju Green Big Bang Committee committed to facilitate the Carbon-Free Island 2030 project in Jeju Island. He is also an advisor to “NEWS 1 Korea” and a columnist of other media. Born in the beautiful volcanic island of Jeju, Korea, Mr. Kim graduated from Seoul National University in 1972 and joined The Hankook Ilbo in 1974 and worked as a journalist for 30 years. Having participated at the Rio Earth Summit in 1992 while dispatched at the newspaper’s United Nations' office, he ingratiated himself into the world of environmental protection and sustainable growth, utilizing his work as a journalist and writer and a his prior studies as a geography major to bring plenty of expertise to current issues and social trends to the movement. He is an alumnus with both the Environmental Policy Course at Seoul National University and the EMBA Course at the Helsinki School of Economics and Business Administration.
Professor, Kookmin University
Woongchul Choi is a Professor of Automotive Engineering at Kookmin University. He received his Bachelor of Science (Mechanical Engineering) from Seoul National University in 1987 and earned his Master of Science and Ph.D. degree both from the Ohio State University in Columbus, Ohio in 1989 and 1995 respectively. He started his professional career as a founding member of a small high tech venture company specializing in the development of stereoscopic image based flow field measurement system and successfully carried out many research projects with major automotive OEMs. His research interest includes vision based 3-D velocimetry, modeling of advanced vehicles for energy analysis, system integration of advanced vehicles for proof-of-concept, thermal management of energy storage systems, bidirectional interaction between vehicles and electric power grid, strategic placement and operation of charging infra-structure and eco-friendly smart city energy analysis. He has been heavily involved in the development of undergraduate and graduate curricula (BK21+, CK II) through government projects as a department chair. Also, he has carried out various government sponsored and private sector (Samsung Electronics, Samsung Electro-Mechanics, Hyundai Motors, SK) sponsored projects including the development of battery swappable electric bus as a public transportation system, battery pack thermal management system, strategy development of charging infrastructure and more.
Recently, he is actively monitoring the charging behavior of electric vehicle owners in Jeju island, Korea to establish the strategy for smart placement of heavily loaded charging infrastructure called EV Charging Theme Park. Last but not least, a preliminary research for Lidar sensor to utilize ~1.5 micrometer wave length laser source is on its way.
CEO, SG H2 Energy
Dr. Do is the author and inventor of Solena Group’s proprietary technology. With graduate degrees in Physics and Medicine from Georgetown University, as well as the Executive MBA program at Harvard University, Dr. Do has over 30 years of experience and expertise as an entrepreneur, scientist and executive, Dr. Do is responsible for the overall strategy, technology offering and management of the company.
As CEO, Dr. Do has led the growth of Solena Group into a multinational company. He has worked with airlines, waste management companies, government agencies and municipalities around the world including in the United States, United Kingdom, Turkey, Russia, Ukraine, Germany, Sweden, Norway, Denmark, Finland, France, Italy, Spain, Portugal, Indonesia, Malaysia, China, Hong Kong, Singapore, Thailand, Brazil and Mexico.
Vice President, SolarEdge
Dimitrios Papadogonas is Vice President of Marketing, North America for SolarEdge Technologies, a global leader in smart energy and the world’s largest manufacturer of PV systems. Prior to joining SolarEdge, Dimitrios was the CMO for iCracked, a Silicon Valley based technology company that operated the world's largest on-demand network for smartphone repairs. At ChargePoint, a global leader in electric vehicle charging, Dimitrios was the Vice President of Marketing where he helped make ChargePoint a household word with EV drivers. At Virgin America, he led the marketing efforts to launch the airline and make it into America’s most loved airline. While at Apple, he played a key role in launching Apple retail stores—bringing the Apple Genius Bar to life. Dimitrios was born in the Netherlands and grew up in Canada. He holds a business degree from the University of Alberta.
Senior Advisor, New Paradigm Institute
Dr. Jung-Hwan KIM is a Senior Advisor of New Paradigm Institute (NPI) for Korea-Silicon Valley Business Forum, where he advises on the platform’s strategic development and partnership program.
After serving at the World Economic Forum (WEF) based in Geneva, Switzerland as a Global Leadership Fellow for the Asia Pacific, Dr. Kim served for the Presidential Committee on Green Growth (Korea) as Director of East Asia Climate Partnership (EACP) Initiative, which was the Korean government’s climate action fund for developing countries, followed by a Senior Program Manager in the Public-Private Cooperation Unit at Global Green Growth Institute (GGGI), where he led the Institute’s private sector engagement program. Recently, He served as International Country Coordinator for Korea at the Asian Development Bank (ADB) for a Technical Assistance Project (Strategy for Northeast Asia Power System Interconnection) and a Regional Advisor for Asia at the Green Climate Fund (GCF). With an engineering and technology background from Korea, Dr. Kim led the Public Affairs program as Deputy Managing Director of Aramco Asia Korea and also gained over ten years’ experience within the private technology sectors in the Asia Pacific and Europe, including IBM, Oracle, and Dell Corporation.
Dr. Kim is specialized in policy science in climate change and energy with Ph. D from the Interdisciplinary Course on Climate Change, Sejong University (Korea) and also graduated with an MBA from the Judge Business School, University of Cambridge (UK), where he studied innovation and entrepreneurship from social and sustainable perspectives and corporate social responsibilities where his leadership interests in the public-private partnership. Also, he earned an Executive Master in Global Leadership from the World Economic Forum’s Global Leadership Fellowship. Through the Fellowship at the World Economic Forum, he gained in-depth exposure to a wide range of global and regional agenda and leadership experience
Bluespace.ai, a new autonomous driving startup focused on mass transit. The startup develops software systems for autonomous mass transit fleets and is currently in meetings with cities and transit providers. Its founding team includes CEO Joel Pazhayampallil, previously co-founder of Drive.ai, which was acquired by Apple earlier this year, and president and COO Christine Moon, whose experience includes serving as head of partnerships for Google’s Nexus program.
Bluespace.ai’s team also has people who have worked at AV companies like Zoox, Lyft Level 5 and Voyage. Their combined experience includes launching AV fleets in Texas, California and Florida. Bluespace.ai’s specific focus is on increasing the overall ability and efficiency across trunk transit routes with higher rider capacity. While other startups have primarily focused on first- and last-mile solutions for slow-speed vehicles that are part of main transit systems, Bluespace.ai’s aim is to safely enable full-size vehicles that can travel on public roads at road speed, therefore serving more passengers at a time.
Ms. Christine Moon, COO: Christine Moon thrives on impacting millions of lives through technology and working with a passionate group of people to shape the future together. BlueSpace.ai is powering the future of urban mobility with its AV (autonomous vehicle) software technology. Taking a faster and safer approach to driverless to enable commercialization. Having spent 15+ years in Silicon Valley, Christine's been a pioneer in emerging tech - self-driving, genomics, cloud and mobile. What matters the most is the people you’re on the journey with. Christine is a Fulbright and Rotary scholar, Yale Fellow. Attended Yale and Yonsei University. LI profile: https://www.linkedin.com/in/3moons1virgo/
CEO, House of Rainmakers
• CEO, House of Rainmakers
• A member of Evaluation Committee for Smart City Project, Ministry of Land, Infrastructure and Transport (Korea)
• A member of Advisory for Smart Factory, Korea Management Association Consultants Inc (Korea)
• A member of Planning Committee, International Electric Vehicle Expo (Korea)
• (Ex) Senior Officer of Innovation Centre of Denmark in Korea, Embassy of Denmark (Korea)
• (Ex) Regional Head for ICT Sector in Korea & Japan, The Ministry of Foreign Affairs (Denmark)
• (Ex) Advisor for EUREKA EurostarsProgrammeon Danish side, The Ministry of Foreign Affairs (Denmark)
• (Ex) Advisor for Business Development, UNIwise(Denmark)
• (Ex) External Director for Business Development in Asia, Audiowise(Denmark)
- Host & Co-producer for series about Global Smart City, Arirang Prime, Arirang TV (Korea)
- A member of Jury for Born Global Programme, Ministry of SMEs and Startups (Korea)
- Mentor for ‘Global Start-up Accelerating Programmeto Denmark & UK, Korea Institute of Startup & Entrepreneurship Development (Korea)
- Special Judge for Final Round, Hi Tech Startup 2017, National IT Industry Promotion Agency (Korea)
- Mentor, Start-up Bootcamp, Rainmaking Loft (Denmark)
Associate Dean, The University of British Columbia Vancouver, Canada
Dr. Walter Mérida Associate Dean, Research and Partnerships Faculty of Applied Science The University of British Columbia Vancouver, Canada: Dr. Mérida is a mechanical engineering professor and the associate dean of Research and Industrial Partnerships. He has worked on clean energy solutions for more than twenty years and is the former director of the Clean Energy Research Centre (CERC). Walter currently leads the Transportation Futures Group at the Pacific Institute for Climate Solutions, who has developed industry-led consortia on clean energy technologies. He also serves on the Board of Directors for the Canadian Urban Transit Research and Innovation Consortium, the Canadian Hydrogen and Fuel Cell Association, and the Institute for Breakthrough Energy Technologies. In 2016, he was recognized as one of Canada’s Clean50, and in 2017, he received a Wall Scholar Research Award from the Peter Wall Institute for Advanced Studies. LI profile https://www.linkedin.com/in/merida/
CEO, Intelligent Structures
Dr. Brian J. Westcott, Chief Executive Officer, Intelligent Structures: Brian is an executive leader with over twenty-five years of global experience in corporate management and governance, business strategy, innovation, marketing, and strategic management of technology, ranging from Board level policy and management for Fortune 500 companies to CEO of venture backed start-ups. He has a creative ability to develop high performing businesses by increasing innovation, improving productivity and providing better leadership, management and business processes. Brian’s industry focus in enterprise software, industrial information and control (IoT and Industrial Internet) and business services, and he has applied digital technology to transforming the markets of medical products, energy, clean-tech, industrial equipment and management consulting. Brian’s held executive management positions with General Electric, AT Kearney Technologies and JDSU, and previously CEO of PurFresh, eInnovatte, and WESTT, Inc. He holds a Bachelor’s degree in Mechanical Engineering from Lehigh University and a Master’s Degree in Control Systems Engineering, and PhD in Management Science from Stanford University. LI profile: https://www.linkedin.com/in/brian-westcott-0358043/
CEO, NXM Labs
NXM Labs is the leader in Autonomous Security software technology that enables connected devices to automatically defend themselves and recover from cyberattacks. NXM partners with global leaders in communications, semiconductors, insurance, manufacturing, transportation, aerospace and government to develop next generation security and edge computing solutions. More information can be found at https://www.nxmlabs.com/
Mr. Scott Rankine, CEO: Scott Rankine is a serial entrepreneur with a track record for building world-class teams and products. Scott launched MGI Software, the global market leader in consumer digital imaging software that achieved a $1.5B public market cap. LI profile: https://www.linkedin.com/in/csrankine/